1 1

Cited 0 times in

Cited 0 times in

Secukinumab Efficacy Predictors in Korean Hidradenitis Suppurativa: A 48-Week Clinical Trial Analysis

Authors
 Ha Nguyen, Ngoc  ;  Lee, Sang Gyu  ;  Ham, Seoyoon  ;  Lee, Ju Hee  ;  Lee, Young In 
Citation
 DERMATOLOGY PRACTICAL & CONCEPTUAL, Vol.15(4), 2025-10 
Article Number
 e20255933 
Journal Title
 DERMATOLOGY PRACTICAL & CONCEPTUAL 
ISSN
 2160-9381 
Issue Date
2025-10
Keywords
Hidradenitis Suppurativa ; Secukinumab ; Korean Patients ; Predictive Factors ; IHS4-55
Abstract
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels commonly occurring in body folds. The IL-17A inhibitor, secukinumab, has shown efficacy in reducing HS lesions in clinical studies, but data on epidemiologic and patient-specific factors influencing response remain limited. Objectives: To assess how baseline disease severity, treatment initiation delay, and prior biologics exposure influence clinical response to secukinumab and patterns of antibiotic use. Materials and Methods: This 48-week real-world prospective trial enrolled 10 Korean patients with moderate-to-severe HS. Patients received secukinumab 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every two weeks. Outcomes included Hidradenitis Suppurativa Clinical Response (HiSCR), a 55% reduction in the International HS Severity Score System (IHS4-55), mean change in abscesses and inflammatory nodules, a >= 30% reduction in pain score on a numeric rating scale (NRS30), and duration of concomitant antibiotic use. Results: At week 48, 90% of patients achieved HiSCR, with 90% meeting the IHS4-55 threshold and 60% reaching the NRS30 criteria. Faster responses were recorded in subjects with Hurley stage II, treatment delays of <10 years, or no prior biologics use, although response rates equalized by week 48. All patients, particularly moderate cases, either discontinued or transitioned to monotherapy with systemic antibiotics. Conclusions: Secukinumab demonstrated efficacy in alleviating HS symptoms in moderate-to-severe cases. Patients with less severe disease, shorter treatment delays, and/or no prior biologic therapy exhibited more rapid initial responses. Additionally, the majority of patients experienced a significant duration of antibiotic cessation, underscoring the importance of early intervention. Future studies with larger populations are required to substantiate these findings.
Files in This Item:
90464.pdf Download
DOI
10.5826/dpc.1504a5933
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Young In(이영인) ORCID logo https://orcid.org/0000-0001-6831-7379
Lee, Ju Hee(이주희) ORCID logo https://orcid.org/0000-0002-1739-5956
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/209638
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links